> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest Federal Register Notices
- URL: https://www.fdaweb.com/latest-federal-register-notices-172/
- Published: 2018-03-25T12:00:00.000Z
- Updated: 2026-09-14T23:55:05.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5141066

[**Info Collection Extension for In Vivo Radiopharmaceuticals Regs**](https://www.fdaweb.com/info-collection-extension-for-in-vivo-radiopharmaceuticals-regs/)  
*Federal Register* notice: FDA sends for OMB approval an information collection extension for “Regulations for In Vivo Radiopharmaceuticals Used for Diagnosis and Monitoring.” 03/23/2018 

[**Antimicrobial Drugs Panel Meeting on Achaogen NDA**](https://www.fdaweb.com/antimicrobial-drugs-panel-meeting-on-achaogen-nda/)  
*Federal Register* notice: FDA announces a 5/2 Antimicrobial Drugs Advisory Committee meeting on an Achaogen NDA for plazomicin. 03/23/2018 

[**CBER Science Symposium Planned for June**](https://www.fdaweb.com/cber-science-symposium-planned-for-june/)  
*Federal Register* notice: FDA announces a 6/25-26 public symposium entitled “2018 Center for Biologics Evaluation and Research Science Symposium.” 03/22/2018  
  
[**Several Information Collections Approved by OMB**](https://www.fdaweb.com/several-information-collections-approved-by-omb/)  
*Federal Register* notice: FDA announces OMB approval of several information collections. 03/22/2018 

[**Draft Guide on Postmarketing Safety Reporting**](https://www.fdaweb.com/draft-guide-on-postmarketing-safety-reporting/)  
*Federal Register* notice: FDA makes available a draft guidance entitled “Postmarketing Safety Reporting for Combination Products.” 03/21/2018 

[**Guide on Combo Product Safety Reporting Compliance**](https://www.fdaweb.com/guide-on-combo-product-safety-reporting-compliance/)  
*Federal Register* notice: FDA makes available an immediately in effect guidance entitled “Compliance Policy for Combination Product Postmarketing Safety Reporting.” 03/21/2018 

[**Comments Extended on Homeopathic Drug Guidance**](https://www.fdaweb.com/comments-extended-on-homeopathic-drug-guidance/)  
*Federal Register* notice: FDA extends by 60 days the comment period on a 12/20/2017 Federal Register notice entitled “Drug Products Labeled as Homeopathic; Draft Guidance.” 03/20/2018 

[**Guide on ‘Small Business’ Determination**](https://www.fdaweb.com/guide-on-small-business-determination/)  
*Federal Register* notice: FDA makes available a draft guidance on how to determine the number of employees for purposes of a “small business” definition. 03/19/2018 

[**Public Workshop on Pathways to Global Unity**](https://www.fdaweb.com/public-workshop-on-pathways-to-global-unity/)  
*Federal Register* notice: FDA announces a 6/11-12 public workshop on “Pathways to Global Unity.” 03/19/2018